Stock Groups

Healthcare group Sanofi targets Dupixent peak sales of over 13 billion euros -Breaking

by Mike Robinson

[ad_1]

© Reuters.

PARIS (Reuters). – French Healthcare Group Sanofi (NASDAQ): Despite being behind its rivals in the race of COVID-19 vaccids, Dupixent has increased Tuesday its sales targets for eczema treatments to 13 billion euros ($14.3billion).

Sanofi stated in a statement that “The new ambition doesn’t include the potential for additional sales ambition upgrades from chronic obstructive lung disease (COPD), with pivotal readingouts expected in 2023.”

Analysts at JP Morgan, an investment bank, stated this month that they expect Sanofi’s peak sales guidance for Dupixent will rise to around $15 billion.

Sanofi has partnered with GlaxoSmithKline (NYSE) in the development of a COVID-19 vaccination.

($1=0.9096 euros)

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is among the most risky investment options. Please make sure you are fully aware of all the costs and risks involved.

[ad_2]